The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Young Jonathan since 2020.
This trader's CIK number is 1779805.
At the time of last reporting, Young Jonathan was the Chief Operating Officer of Akero Therapeutics, Inc.. (stock ticker symbol AKRO).
Also see all insider trading activities at Akero Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | AKRO | 0 | $0 | 99,553 | $4,476,630 | 68,064 | $801,559 |
| 2024 | AKRO | 0 | $0 | 141,954 | $4,178,938 | 80,716 | $1,702,300 |
| 2023 | AKRO | 0 | $0 | 37,547 | $664,464 | 5,904 | $44,772 |
| 2022 | AKRO | 0 | $0 | 25,000 | $1,178,562 | 52,744 | $140,162 |
| 2021 | AKRO | 0 | $0 | 65,835 | $1,712,987 | 16,500 | $10,147 |
| 2020 | AKRO | 0 | $0 | 0 | $0 | 50,024 | $30,763 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | AKRO | Sale | 12,500 | 46.83 | 585,387 |
| 2025-09-02 | AKRO | Option Ex | 12,500 | 21.10 | 263,750 |
| 2025-08-12 | AKRO | Option Ex | 12,500 | 21.10 | 263,750 |
| 2025-08-12 | AKRO | Sale | 12,500 | 48.02 | 600,275 |
| 2025-06-18 | AKRO | Sale | 1,453 | 54.84 | 79,682 |
| 2025-06-10 | AKRO | Sale | 2,493 | 53.99 | 134,604 |
| 2025-03-12 | AKRO | Sale | 607 | 44.88 | 27,242 |
| 2025-03-04 | AKRO | Sale | 50,000 | 44.62 | 2,231,000 |
| 2025-02-03 | AKRO | Sale | 10,000 | 53.81 | 538,110 |
| 2025-01-24 | AKRO | Option Ex | 43,064 | 6.36 | 274,059 |
| 2025-01-02 | AKRO | Sale | 10,000 | 28.03 | 280,330 |
| 2024-12-10 | AKRO | Sale | 2,503 | 30.79 | 77,067 |
| 2024-12-02 | AKRO | Sale | 10,000 | 32.13 | 321,310 |
| 2024-11-01 | AKRO | Sale | 50,716 | 32.15 | 1,630,671 |
| 2024-11-01 | AKRO | Option Ex | 40,716 | 21.09 | 858,700 |
| 2024-10-14 | AKRO | Sale | 40,000 | 30.15 | 1,206,080 |
| 2024-10-14 | AKRO | Option Ex | 40,000 | 21.09 | 843,600 |
| 2024-10-01 | AKRO | Sale | 10,000 | 28.18 | 281,770 |
| 2024-09-10 | AKRO | Sale | 568 | 26.18 | 14,870 |
| 2024-08-01 | AKRO | Sale | 5,000 | 26.84 | 134,175 |
| 2024-07-01 | AKRO | Sale | 5,000 | 23.40 | 117,020 |
| 2024-06-11 | AKRO | Sale | 2,516 | 22.64 | 56,964 |
| 2024-06-03 | AKRO | Sale | 5,000 | 19.29 | 96,440 |
| 2024-05-01 | AKRO | Sale | 5,000 | 20.15 | 100,750 |
| 2024-04-01 | AKRO | Sale | 5,000 | 24.68 | 123,379 |
| 2024-03-13 | AKRO | Sale | 651 | 28.33 | 18,442 |
| 2023-12-27 | AKRO | Sale | 5,414 | 24.00 | 129,936 |
| 2023-12-27 | AKRO | Option Ex | 5,414 | 6.36 | 34,433 |
| 2023-12-14 | AKRO | Sale | 543 | 20.76 | 11,272 |
| 2023-11-17 | AKRO | Sale | 30,000 | 14.68 | 440,250 |
| 2023-10-02 | AKRO | Option Ex | 490 | 21.10 | 10,339 |
| 2023-10-02 | AKRO | Sale | 490 | 51.10 | 25,039 |
| 2023-09-13 | AKRO | Sale | 562 | 50.34 | 28,291 |
| 2023-06-13 | AKRO | Sale | 538 | 55.16 | 29,676 |
| 2022-12-27 | AKRO | Option Ex | 12,500 | 3.49 | 43,600 |
| 2022-12-27 | AKRO | Sale | 12,500 | 49.57 | 619,612 |
| 2022-10-25 | AKRO | Option Ex | 12,500 | 6.36 | 79,500 |
| 2022-10-25 | AKRO | Sale | 12,500 | 44.72 | 558,950 |
| 2022-01-07 | AKRO | Option Ex | 27,744 | .61 | 17,062 |
| 2021-11-04 | AKRO | Sale | 6,220 | 24.33 | 151,332 |
| 2021-11-03 | AKRO | Sale | 18,780 | 24.27 | 455,790 |
| 2021-09-01 | AKRO | Sale | 12,500 | 24.04 | 300,500 |
| 2021-07-15 | AKRO | Option Ex | 9,000 | .61 | 5,535 |
| 2021-06-01 | AKRO | Sale | 3,055 | 26.24 | 80,150 |
| 2021-05-03 | AKRO | Sale | 3,055 | 30.56 | 93,360 |
| 2021-04-01 | AKRO | Sale | 3,055 | 28.75 | 87,828 |
| 2021-03-01 | AKRO | Sale | 3,055 | 30.80 | 94,094 |
| 2021-02-01 | AKRO | Sale | 3,055 | 29.55 | 90,290 |
| 2021-01-08 | AKRO | Sale | 10,000 | 28.12 | 281,200 |
| 2021-01-07 | AKRO | Option Ex | 7,500 | .61 | 4,612 |
| 2021-01-04 | AKRO | Sale | 3,060 | 25.64 | 78,443 |
| 2020-03-13 | AKRO | Option Ex | 11,117 | .61 | 6,836 |
| 2020-01-10 | AKRO | Option Ex | 38,907 | .61 | 23,927 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Young Jonathan (Chief Operating Officer of Akero Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.